
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cvs Group Plc | LSE:CVSG | London | Ordinary Share | GB00B2863827 | ORD 0.2P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
1,256.00 | 1,260.00 | 1,270.00 | 1,248.00 | 1,260.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Veterinary Svcs-animal Specs | 664.8M | 6.2M | 0.0864 | 146.06 | 892.45M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
15:19:49 | O | 530 | 1,261.3654 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
10/6/2025 | 08:54 | UK RNS | CVS Group plc Response to CMA announcement |
02/6/2025 | 12:56 | UK RNS | CVS Group plc Director/PDMR Shareholding |
30/5/2025 | 12:54 | UK RNS | CVS Group plc Total Voting Rights |
19/5/2025 | 10:11 | ALNC | ![]() |
19/5/2025 | 07:00 | UK RNS | CVS Group plc Completion of Crematorium Operations Disposal |
08/5/2025 | 17:25 | UK RNS | CVS Group plc Standard form for notification of major holdings |
30/4/2025 | 07:00 | UK RNS | CVS Group plc Total Voting Rights |
24/4/2025 | 07:00 | UK RNS | CVS Group plc Disposal of Crematorium Operations |
31/3/2025 | 07:00 | UK RNS | CVS Group plc Total Voting Rights |
28/3/2025 | 15:03 | UK RNS | CVS Group plc PDMR Dealing |
Cvs (CVSG) Share Charts1 Year Cvs Chart |
|
1 Month Cvs Chart |
Intraday Cvs Chart |
Date | Time | Title | Posts |
---|---|---|---|
18/6/2025 | 21:54 | CVS Group: VETS,All things bright and beautiful | 1,021 |
07/10/2019 | 20:38 | Concerns founded? | 33 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
14:19:50 | 1,261.37 | 530 | 6,685.24 | O |
14:13:20 | 1,261.16 | 1 | 12.61 | O |
14:12:59 | 1,262.00 | 90 | 1,135.80 | AT |
14:12:59 | 1,262.00 | 87 | 1,097.94 | AT |
14:12:59 | 1,262.00 | 45 | 567.90 | AT |
Top Posts |
---|
Posted at 20/6/2025 09:20 by Cvs Daily Update Cvs Group Plc is listed in the Veterinary Svcs-animal Specs sector of the London Stock Exchange with ticker CVSG. The last closing price for Cvs was 1,244p.Cvs currently has 71,740,184 shares in issue. The market capitalisation of Cvs is £905,361,122. Cvs has a price to earnings ratio (PE ratio) of 146.06. This morning CVSG shares opened at 1,260p |
Posted at 02/5/2025 14:27 by wad collector Surprised how strong this bounce has become, considering there were no firm conclusions yesterday. Another £2 and I will be back in the blue.Here is the BVA initial response; “Many of the CMA’s potential remedies are absolutely hitting the right note, particularly around the need for greater transparency and better communication and it’s good to see the CMA acknowledging the steps the profession has taken to address these with BVA support. “There are, however, some concerns around the potential remedies outlined in the consultation papers, particularly around medicines, out of hours care, cremations and standardised price lists. We will look closely at the detail of these in the coming weeks and formally respond to the CMA. It’s vital that any measures the CMA presses forward with do not risk undermining the ability of veterinary professionals to do their job or compromise the sustainability of the sector, which could have negative consequences for the welfare of the animals in our care.” |
Posted at 17/3/2025 09:13 by wad collector Surprising rise, I wondered if there was a CMA update but cannot see one. Surprised one broker tip would add 10% to share price More detail on above On Monday, RBC Capital Markets adjusted their stance on CVS Group Plc (LON:CVSG)., a veterinary services provider listed on the London Stock Exchange (LON:LSEG) (CVSG:LN) and over-the-counter (OTC: CVSGF), elevating the stock from ’Sector Perform’ to ’Outperform The revision by RBC Capital’s analyst Charles Weston is grounded in a positive evaluation of CVS Group’s operational margins within its Australian practices. Weston noted that these margins are accretive and may not be fully appreciated by the investment community. The analyst also pointed out that clarity regarding potential investigations by the Competition and Markets Authority (CMA) in the UK is expected to be reached soon. This clarification could potentially drive investor interest, especially considering the current undervalued state of the company’s shares. Weston’s commentary suggests that despite the challenging consumer environment, CVS Group’s strong industry fundamentals are likely to be recognized by investors once there is more confidence surrounding the CMA’s findings. The anticipation of this outcome seems to have played a significant role in the decision to upgrade the stock rating. The price target increase to £15.00 reflects a substantial uplift from the previous target of £9.40. This new target is predicated on the belief that once investors adjust their non-operating cost assumptions and gain confidence regarding the CMA’s position, they will be more inclined to factor in the robust industry dynamics and the high margins from the Australian practices into CVS Group’s valuation. |
Posted at 17/3/2025 07:24 by bigbigdave RBC RAISES CVS GROUP TO 'OUTPERFORM' (SECTOR PERFORM) - PRICE TARGET 1500 (940) PENCE |
Posted at 27/2/2025 12:14 by gibbs1 CVS nurses pet sector weakness as private equity rumours circle rivalBy JANE DENTON Updated: 11:11 GMT, 27 February 2025 Veterinary business CVS Group saw sales struggle for momentum in the second half of 2024 as the pet sector continues to lag its pandemic era strength. CVS revenues jumped over 6 per cent to £341.8million in the six months to 31 December, the group said on Thursday. But like-for-like sales were 1.1 per cent lower compared to the first half of 2024, as previously guided, having been hit by a 'continuation of softer market conditions in the UK most notably in the Group's online retail and laboratory businesses'. The company saw its pre-tax profit fall in the period amid increased finance expenses and depreciation costs. Reported profit before tax on continuing operations fell 35.1 per cent to £17.4million. CVS has been actively expanding in Australia, completing several acquisitions and identifying synergies to enhance returns. This week market chatter suggested that a European private equity firm may look at taking over Pets at Home. It has been claimed that the potential bidder could be based in Europe and have a similar business to FTSE 250-listed Pets at Home in the US. But Pets at Home did not comment on the speculation on Thursday. David Hughes, equity analyst at Shore Capital, said this suggests 'that no formal approach has happened'. He added: 'The veterinary sector has been under review from the CMA, however recent comments suggest a softening of the regulators stance here, perhaps fuelling any M&A rumours in the sector.' CVS Group shares fell 2.41 per cent or 25.50p to 1,032.50p, having fallen over 37 per cent in the last year. Pets at Home shares were down 1.05 per cent or 2.60p to 245.60p on Wednesday, having fallen over 13 per cent in the last year. Looking ahead, CVS highlighted 'headwinds in the UK and employment cost increases resulting from the UK Autumn Budget', but said 'the fundamental need for high-quality veterinary care remains strong'. THIS IS MONEY Derren Nathan, head of equity research at Hargreaves Lansdown, said: 'Veterinary services provider CVS Group’s first half trading had little to set tails wagging with like-for-like sales still in negative territory.' The UK's Competition and Markets Authority has been probing the veterinary sector amid concerns pet owners are being overcharged. Vet groups could be forced to cap prescription fees, sell off parts of their business or give mandatory information to pet owners if the probe finds it necessary. It follows warnings in March 2024 about weak market competition, partly caused by rapid sector consolidation. Nathan said: 'There was no reference to any potential remedies today, only continuing uncertainty, which is driving a much more selective approach to acquisitions in the UK. 'The focus for consolidation remains on Australia where eight practice sites have been acquired so far this year with £23million paid up front.' He added: 'It’s inorganic growth that’s powering the modest additions seen to the Group’s top and bottom line so far this year and if hopes for an improved second half in the UK can be achieved the overall picture could improve substantially. 'Despite a recent recovery, the earnings-based valuation is still around half the long-run average, which could offer investors an opportunity to gain exposure to a high-quality business with attractive long-term growth drivers. 'The CMA enquiry remains a risk but could also prove to be a catalyst if price controls aren’t part of the recommendations.' In May 2024, the Competition and Markets Authority confirmed its decision to launch a market investigation into veterinary services. In July, the CMA published an issues statement which set out the scope of the investigation and the areas being explored. |
Posted at 27/2/2025 07:39 by typo56 This is what got PETS excited yesterday, but could the target be CVSG? |
Posted at 26/2/2025 11:39 by babbler I guess cvsg has had more of a recovery since the dip than Pets Has. But yes...if confirmed then another 40% easy here. |
Posted at 12/2/2025 22:40 by lomax99 Impact - other than cratering the share price for no good reason! |
Posted at 20/11/2024 07:59 by waldron DividendSubject to shareholder approval at the AGM, CVS intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024. Outlook Whilst the Board remains mindful of headwinds in the UK, the fundamental need for high quality veterinary care remains strong, the expansion into Australia is progressing well and CVS remains well positioned to deliver attractive growth in shareholder value over the medium term. The recently announced UK government budget changes will result in a significant increase in employment costs with effect from April 2025. Whilst these increases will only apply in the final quarter of this financial year, the annualised impact to the year ending 30 June 2026 is estimated to be £8m from the national insurance scheme changes. The Group expects to substantially mitigate these through growth, efficiencies and purchasing synergies in Australia. The Board remains confident in the Group's ability to deliver full year 2025 results in line with market expectations. |
Posted at 08/10/2024 08:19 by waldron CVS Group (LON:CVSG) Shares Cross Above 200 Day Moving Average - Time to Sell?Written by MarketBeat October 4, 2024 CVS Group plc (LON:CVSG - Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,054.38 ($14.10) and traded as high as GBX 1,124 ($15.03). CVS Group shares last traded at GBX 1,064 ($14.23), with a volume of 349,914 shares changing hands. Get CVS Group alerts: Wall Street Analyst Weigh In Separately, Berenberg Bank reissued a "buy" rating and issued a GBX 2,370 ($31.70) price objective on shares of CVS Group in a research note on Thursday, July 25th. The company has a quick ratio of 0.90, a current ratio of 1.09 and a debt-to-equity ratio of 110.48. The firm has a market capitalization of £760.44 million, a P/E ratio of 2,905.56, a price-to-earnings-gr CVS Group Increases Dividend The company also recently disclosed a dividend, which will be paid on Friday, November 29th. Stockholders of record on Thursday, October 31st will be issued a dividend of GBX 8 ($0.11) per share. This is an increase from CVS Group's previous dividend of $7.50. The ex-dividend date of this dividend is Thursday, October 31st. This represents a dividend yield of 0.71%. CVS Group's payout ratio is currently 2,222.22%. Insider Activity at CVS Group In other CVS Group news, insider Richard Gray bought 1,600 shares of the firm's stock in a transaction dated Wednesday, July 10th. The stock was bought at an average cost of GBX 1,019 ($13.63) per share, with a total value of £16,304 ($21,808.45). 5.83% of the stock is currently owned by insiders. CVS Group plc, together with its subsidiaries, engages in veterinary, pet crematoria, online pharmacy, and retail businesses. The company operates through four segments: Veterinary Practices, Laboratories, Crematoria, and Online Retail Business. It operates in animal veterinary practices and complementary veterinary diagnostic businesses. |
Posted at 26/9/2024 08:20 by wad collector Well that drop didn't last long ;about 15 minutes! Guess the lower numbers were all in the price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions